Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Gen-Probe Tepnel
Gen-Probe Tepnel
Activities:
Regulatory
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Analysis
Gen-Probe adds three to leadership team
To support diagnostic products and services firm’s growth
Research & Development
Gen-Probe’s analytical service laboratories pass FDA inspection
Site already certified by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for GMP, GLP and GCP compliance
Research & Development
Gen-Probe expands service offering in Manchester, UK
Increases footprint and hires two managers
Analysis
FDA clears first nucleic acid amplification test to detect Trichomonas Vaginalis
APTIMA assay will improve detection of a potentially serious sexually transmitted infection that is common in women of all ages
Finance
Biotech Outsourcing Strategies cmc
<b>17 June 2010</b><br> Sohuset Conference Centre, Horsholm, Denmark
Research & Development
NCRI Cancer Conference
<b>7 - 10 November 2010</b><br> Liverpool, UK
Finance
BIO-Europe 2010
<b>15 - 17 November 2010</b><br> Munich, Germany
Subscribe now